Conclusion
Our postapproval, single-center 6-month survival of 93.3% is suggestive
of comparable real-world findings when compared with the MOMENTUM 3
trial patients and the data from the ELEVATE registry. However, similar
findings through multi-institutional studies are needed to confirm these
results.